KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Change in Cash (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Change in Cash for 13 consecutive years, with $94.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Cash rose 71.8% to $94.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $56.5 million, a 1051.8% increase, with the full-year FY2025 number at $56.5 million, up 1051.8% from a year prior.
  • Change in Cash was $94.6 million for Q4 2025 at Xenon Pharmaceuticals, up from -$30.9 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $253.4 million in Q2 2022 to a low of -$266.5 million in Q3 2022.
  • A 5-year average of $7.7 million and a median of $8.6 million in 2021 define the central range for Change in Cash.
  • Biggest YoY gain for Change in Cash was 5113.77% in 2022; the steepest drop was 5562.14% in 2022.
  • Xenon Pharmaceuticals' Change in Cash stood at $87.9 million in 2021, then crashed by 152.63% to -$46.2 million in 2022, then skyrocketed by 206.1% to $49.1 million in 2023, then rose by 12.27% to $55.1 million in 2024, then surged by 71.8% to $94.6 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Change in Cash are $94.6 million (Q4 2025), -$30.9 million (Q3 2025), and $18.7 million (Q2 2025).